The LotusTM Valve System

Aortic valve disease, TAVI and Boston Scientific's LotusTM Valve System



Information for the media

Congress itinerary

BOSTON SCIENTIFIC RECEIVES CE MARK FOR LOTUS™ VALVE SYSTEM

Transcatheter Aortic Valve Replacement (TAVR) Device Offers Precise Positioning and Placement, Offering Physicians Unprecedented Control

Natick, Mass. (Oct. 28, 2013) – Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Lotus™ Valve System, the company’s advanced transcatheter aortic valve replacement (TAVR) technology.  This key approval offers a unique and effective new treatment alternative for patients with severe aortic stenosis at high risk with surgical valve replacement. 

The Lotus Valve System is immediately available to select centers in Europe, with commercial site expansion accelerating as physicians and centers become fully trained. 

BOSTON SCIENTIFIC REPORTS FAVORABLE SIX-MONTH RESULTS FROM LOTUS™ VALVE SYSTEM CLINICAL TRIAL

REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves Course

Natick, Mass. (Sept. 17, 2013) – Boston Scientific Corporation (NYSE: BSX) reported favorable six-month results from the first 60 patients enrolled in the REPRISE II clinical trial evaluating the safety and performance of the Lotus™ Valve System in symptomatic patients with severe aortic stenosis considered at high risk for surgical valve replacement. 

The data, which were presented today at PCR London Valves and formally received the honor of Best Abstract 2013, demonstrated excellent results with no new valve-related adverse events between 30 days and six months. Additionally, there were no cases of moderate or severe...